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 Abstract 
As part of the UK NCRI AML17 trial, adult acute myeloid leukaemia patients in 
remission could be randomised to receive the mTOR inhibitor everolimus, 
sequentially with post-induction chemotherapy. Three hundred and thirty-nine 
patients were randomised (2:1) to receive everolimus or not for a maximum of 
84 days between chemotherapy courses. The primary endpoint was relapse 
free survival (RFS). At 5 years there was no difference in Relapse Free 
Survival (29% vs 40%; OR 1.19 (0.9-1.59) p=0.2), cumulative incidence of 
relapse  (60% vs 54%: OR 1.12( 0.82-1.52): p=0.5) or overall survival (45% vs 
58%: OR 1.3 (0.94-1.81): p=0.11). The independent Data Monitoring 
Committee advised study termination after randomisation of 339 of the 
intended 600 patients due to an excess mortality in the everolimus arm 
without any evidence of beneficial disease control. Dose delivery of 
everolimus was variable, but there was no evidence of clinical benefit in 
patients with adequate dose delivery compared with no treatment. This study 
suggests that the addition of mTOR inhibition to chemotherapy provides no 
benefit. 
 
Introduction 
The majority (70-85%) of younger patients with acute myeloid leukaemia 
(AML) will enter complete morphological remission with any one of a variety of 
induction treatments. However nearly half will relapse. It is increasingly being 
recognised that a substantial proportion of those in morphological remission 
have residual disease as assessed by techniques of minimal/measurable 
residual disease assessment (flow cytometry or quantitative polymerase chain 
reaction1,2). In our previous studies we have endeavoured to define the 
optimum post remission chemotherapy. To date we conclude that, apart from 
transplantation, following two induction courses of anthracycline containing 
therapy, two consolidation courses of Ara-C is adequate3. An aim of the UK 
NCRI AML17 trial was also to explore a further reduction in the total number 
of chemotherapy courses from 4 to 3, as well as the addition of molecularly 
targeted treatments to consolidation therapy. Among these was the 
incorporation of the inhibitor of the mammalian target of rapamycin (mTOR), 
everolimus. 
There is plausible pre-clinical evidence both in vitro and in vivo that mTOR 
inhibition could be beneficial in AML. mTOR is a serine/threonine protein 
kinase that is predominantly modulated by PI3K-AKT-dependent mechanisms 
and acts as a central regulator of cellular metabolism, growth and survival4. 
Dysregulation of the mTOR pathway is closely associated with cancers 
including AML5,6 and other human diseases. Part of the rationale is the 
evidence of constitutive activation of the PI3K-AKT pathway in 90% of AML 
samples and the demonstration that this activation is central to the survival of 
AML blasts but not of normal CD34+ cells7. The concept that everolimus may 
have the potential to eliminate leukaemia-initiating stem cells whilst sparing 
normal haematopoietic stem cells is also appealing. In vivo evidence in 
NOD/SCID mice has suggested that mTOR regulates a critical cell survival 
pathway in AML stem cells8,9. In an preliminary unrandomised clinical trial, the 
mTOR inhibitor sirolimus was administered as a single agent to 9 relapsed, 
refractory or poor-risk AML patients for 28 days resulting in partial responses 
in 4, and stable disease in a 5th patient10.  De-phosphorylation of downstream 
effectors of mTOR was demonstrated. In an ongoing U.K. trial, 11 elderly 
patients with primary and relapsed AML have been treated with the 
combination of low dose Ara-C and sirolimus. Following a single 28-day 
course of treatment, of the 7 patients eligible for analysis, one had achieved a 
CR, 4 a PR, one marrow was profoundly hypocellular and one patient was a 
non-responder (Das Gupta, unpublished data). Patients in this trial reliably 
maintained trough sirolimus levels of 8-16 ng/ml, which are consistent with the 
published concentrations required to inhibit AML cell growth in vitro. The 
feasibility of combining mTOR inhibition (sirolimus) with intensive 
chemotherapy had also been assessed in AML patients in conjunction with 
the more intensive MEC (Mitoxantrone, Etoposide and Cytarabine) 
chemotherapy regimen in a phase I dose escalation study and reported in 
abstract form. In this study standard renal transplant doses of sirolimus were 
well tolerated and did not increase the non- haematological toxicity of MEC 
chemotherapy with a median time to neutrophil recovery of 27 days11. Based 
on this background information, the NCRI AML17 trial included the option for 
eligible patients to be randomised to receive, or not, the mTOR inhibitor 
everolimus daily between consolidation chemotherapy courses. 
 
Methods 
The UK NCRI AML 17 trial (ISRNCTN 55675535) was a large, prospective 
phase 3 multi-centre trial for patients with newly-diagnosed AML or high risk 
myelodysplastic syndrome (MDS; >10% marrow blasts), generally under the 
age of 60 years, open from April 2009 to December 2014 in >130 centres in 
the United Kingdom, Denmark and New Zealand. It addressed several 
randomised questions (supplementary figure 1). Between October 2009 and 
October 2012, 499 adult patients who did not have acute promyelocytic 
leukaemia (APL),  had received the first induction course and who did not 
have Core Binding Factor leukemia, high risk disease (defined using a 
multifactorial score12) and were not in the lestaurtinib randomisation for 
patients with FLT3 mutations, could be randomised between adding  
everolimus, or not in a 2:1 ratio, between subsequent consolidation 
chemotherapy courses.  Treatment schedules have been set out elsewhere13. 
Allogeneic stem cell transplantation was permitted for patients with 
intermediate- or poor-risk disease with a recommendation of myelo-ablative 
conditioning for patients aged <35 years and reduced intensity conditioning 
for intermediate risk patients >45 years, with investigators able to choose an 
ablative or reduced intensity approach for patients between 35 and 45 years.  
Patients eligible to enter the everolimus randomisation included 34% of all 
adult patients entering AML17 while the randomisation was available. Oral 
everolimus (10mg daily from 2 days after each chemotherapy course for up to 
28 days or until 2 days before the start of the subsequent course, whichever 
was shorter) or not was given between each course of consolidation 
chemotherapy.. In patients allocated 3 courses of treatment, a final 28-day 
course of everolimus was given after a one-week break. In patients with side 
effects thought due to everolimus, subsequent doses could be reduced by 
50% in daily dosing. If this did not improve tolerability, dosing could be further 
reduced to alternate days; if these dose reductions were not tolerated, 
subsequent doses would be omitted. After 65% (n=146) of the patients 
randomised to everolimus were assessed, the Independent Data Monitoring 
Committee recommended, because of increased side effects and reduced 
compliance, that the starting daily dose of everolimus be reduced to 5mg with 
the option to increase to 10mg if well-tolerated. 
Extensive Sanger sequencing (111 genes) was undertaken in 123 patients;  
NPM1 status was available in 302 patients.   
Patients were requested to provide a trough blood sample taken immediately 
prior to everolimus dosing on day 14 of each treatment course to measure the 
level of mTOR inhibitory activity in their plasma (PIA). Methods are 
summarised here (supplementary figure 2) and will be more fully reported 
elsewhere. 
 
Statistical considerations:   
All analyses are by intention-to-treat. Categorical endpoints were compared 
using Mantel-Haenszel tests, giving Peto odds ratios and confidence intervals. 
Continuous/scale variables were analysed by Wilcoxon rank sum tests; and 
time-to-event outcomes using the log-rank test, with Kaplan-Meier survival 
curves. Odds/hazard ratios (OR/HR) <1 indicate benefit for everolimus. All 
survival percentages are at 5 years unless otherwise stated. 
Stratified analyses were performed with suitable tests for interaction14 and 
interpreted cautiously.  
It was planned to recruit 600 patients to the everolimus randomisation, giving 
85% power to detect a 12.5% difference in the primary endpoint of RFS, from 
50% to 62.5% (HR 0.68). Follow-up is complete until 1st March 2016 (median 
follow-up from diagnosis 53.5 months (range 4.3 – 76.8 months)).  
The trial was conducted in accordance with the Declaration of Helsinki, 
sponsored by Cardiff University and approved by Wales REC3 on behalf of all 
UK investigators, by the Danish Medicines Agency for sites in Denmark, and 
by MEDSAFE for sites in New Zealand.  
Results 
Patient characteristics: The randomisation opened in October 2009. In 
2012, the Independent Data Monitoring Committee recommended closure of 
the randomisation, because of an excess of early mortality in remission with 
everolimus and no associated evidence of relapse reduction. Between 
October 2009 and October 2012, 332 of 482 eligible patients were 
randomised (Figure 1). Their characteristics are shown in table 1. There was 
no significant survival difference in outcome between eligible patients who 
entered the randomisation and those who did not (p=0.8), although patients 
with higher WBC, worse performance and secondary disease were marginally 
less likely to enter the randomisation. The median age was 47 years (range 
16-69). The majority presented with de novo AML and had a WHO 
performance score of <2. The other protocol treatments given to patients in 
the everolimus randomisation are shown in table 1. In addition to standard 
daunorubicin/Ara-C induction additional etoposide and gemtuzumab 
ozogamicin was given to 43% and 45% of patients respectively in induction 
with no difference between arms.  
Overall, 132/332 (40%) of patients received a transplant (everolimus 39%, 
control 42%, p=0.6), with a minority of these (34/132) being allografts in first 
remission (20 vs 14; p=0.3). There was no evidence of differences in 
transplantation rates or types of transplants between the arms (any SCT 39% 
vs 42%; p=0.6; allograft  31% vs 34% p-0.6; allograft in CR1 9% vs 13%, 
p=0.3; Table 1).  
Extensive Sanger sequencing (111 genes) was undertaken in 123 patients, 
and the gene panel and distribution is shown in supplementary figure 3. In 
addition NPM1 status using previously published methods, was available in 
302 patients.   
 
Treatment compliance: Of the 220 patients allocated to receive everolimus, 
16 never started therapy. Approximately 25% of patients did not receive 14 
days of everolimus; about half completed the first 28 day course. At the time 
of the second course of everolimus (course 3 of chemotherapy), 35% of 
patients with second everolimus course  information did not receive drug 
(figure 2). Reasons were given for about two thirds of patients (39/61) – 11 
patients had not completed the previous course; 11 patients chose to 
discontinue (often because of toxicity in the previous course), in 3 cases the 
DMC had recommended closure and stopping treatment; in 5 cases patients 
did not reach the starting point for everolimus therapy on protocol; in 2 cases 
the clinician decided, and in 4 other cases, everolimus was not given due to a 
variety of toxicities.  
Toxicity: The recorded toxicities are shown in figure 3. There was more 
haematological toxicity in the everolimus arm which was most obvious after 
the first everolimus course, with median time to  platelet recovery to >100 x 
109/L being 9 days longer (39 vs 29 days; p= 0.006), which was reflected in a 
significantly greater requirement for platelet support.(table 3). The kinetics of 
neutrophil recovery was unaffected by everolimus, but there was significantly 
more use of antibiotics and a longer hospital stay with the first course of 
everolimus, as well as increased oral toxicity (course 1) and higher alanine 
transaminase levels (course 2).  
 
Cumulative Risk of Relapse and Death in Remission:  The overall 
outcomes are shown in table 2. The cumulative incidence of relapse at 5 
years (figure 4a) did not differ significantly between arms (60% vs 54%, HR 
1.12 (0.82-1.52), p=0.5). There was a significant excess of deaths in 
remission in the everolimus arm in the first 6 months following randomisation 
(8% vs 1%, HR 3.57 (1.36-9.42), p=0.009), with no significant differences 
thereafter leading to a non-significant excess of overall mortality with 
everolimus (11% vs 6%, HR 1.75 (0.83-3.70), p=0.14, Figure 4b). The causes 
of death in remission were: in the first 6 months 17 vs 1 (infection 9 vs 1; 
infection+haemorrhage 3 vs 0; haemorrhage/CVA 3 vs 0; cardiac 1 vs 0; 
multiple 1 vs 0); beyond 6 months 6 vs 6 (infection 1 vs 1; cardiac 1 vs 0; 
hepatic 1 vs 0; second cancer 1 vs 0; GVHD 0 vs 1; multiple 0 vs 2; 
unknown/other 2 vs 2). 
 
Relapse Free and Overall Survival: Both relapse free and overall survival 
were non-significantly inferior in the everolimus arm, (figures 4c and 
d),reflecting the adverse hazard ratios for both relapse and death in 
remission, and no evidence of differences in salvage between arms after 
relapse (RFS: 29% vs 40%, HR 1.19 (0.90-1.59), p= 0.2; OS: 45% vs 58%, 
HR 1.30 (0.94-1.81), p=0.11). A sensitivity analysis, censoring patients at 
stem cell transplant showed results which were consistent with the overall 
analysis (table 2). 
 Exploratory Analyses: The correlation with PIA did not show a convincing 
pattern. Using this assay, even patients whose samples showed deep and 
sustained inhibition, did not have an associated reduction in relapse 
(supplementary figure 2). There was no relationship between the level of 
inhibition and toxicity or excess mortality. Prior induction chemotherapy, age, 
gender, WBC, and minimal residual disease status after course one, all had 
no impact on outcomes (Supplementary Figure 4A). In addition no relationship 
between other treatment modalities given and response was found, and no 
gene mutation, including the 110 genes assayed by Sanger sequencing in 
123 patients showed a differential response (Supplementary Figure 5). 
Because of concerns about compliance with everolimus treatment, RFS was 
compared between patients with satisfactory drug delivery (defined as at least 
14 days of treatment per course), those with inadequate drug delivery (less 
than 14 days treatment per course) and those allocated to no treatment. 
Although inadequate drug delivery (n=85) had a worse RFS (29%) there was 
no difference in RFS between patients with satisfactory drug delivery (n=63) 
at 41% and no everolimus (n=99) at 40%(supplementary figure 4).  
 
Discussion 
In this trial there was no benefit of the addition of the mTOR inhibitor 
everolimus to post-induction chemotherapy, despite the pre-clinical in vitro 
and in vivo rationale for its use. The main observed explanation appears to be 
excess toxicity, which was primarily gastrointestinal (mucositis and diarrhoea) 
and biochemical evidence for liver toxicity at the dose chosen. Infection was a 
major issue in the first 6 months of treatment with 12 vs 1 deaths attributed to 
infection. This did not appear to be the result of prolonged neutropenia but 
may be attributable to the immunosuppressive effects of everolimus when 
given with chemotherapy, which reflects what has been seen with its use in 
solid tumours15. This in turn contributed to sub-optimal drug delivery for many 
patients. The chosen schedule of 10mg daily was not feasible in this setting, 
but drug delivery improved when a 5mg daily dose was introduced. Other 
studies in leukaemia have used equivalent schedules16,17 or a loading dose 
(12mg) followed by 4mg/day for 7 days per cycle11 or lower doses in 
combination with low dose Ara-C18. However even when the subgroup of 
good compliers was compared separately, there was no evidence of improved 
disease control.  
We had hoped that the development of an assay to quantitate PIA would 
provide insight to response or toxicity, but unlike the experience of PIA in the 
setting of FLT3 inhibitor19,20, this was not found to be consistent. In a phase 2 
study in relapsed AML treated with clofarabine and temsirolomus, correlation 
of response to dephosphorylation of pS6RP (S6 ribosomal protein) was 
demonstrated.21 However the target cells were the patient’s own blasts, which 
were not available in the current study and it was unclear if the clinical 
outcome was superior to that which clofarabine alone could achieve. 
Finally the mTOR inhibitors tested to date have been inhibitors of the TORC1 
pathway. This may be by-passed by the TORC2 pathway which is insensitive 
to this class of mTOR inhibitors, but may be sensitive to agents which have 
dual inhibition. 
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 Table 1: Patient Characteristics 
 
Characteristic Everolimus 
(n=220) 
Control 
(n=112) 
Age: 
16-29 
30-39 
40-49 
50-59 
60+ 
Median 
Range 
 
33 (15%) 
36 (16%) 
58 (26%) 
73 (33%) 
20 (9%) 
48  
16-69 
 
 
 
16 (14%) 
17 (15%) 
31 (28%) 
37 (33%) 
11 (10%) 
46 
17-66 
Sex: 
Female 
Male 
 
117 (53%) 
103 (47%) 
 
70 (63%) 
42 (37%) 
Diagnosis: 
De Novo 
Secondary 
MDS 
 
203 (92%) 
5 (2%) 
12 (5%) 
 
103 (92%) 
3 (3%) 
6 (5%) 
WHO PS: 
0 
1 
2 
3 
4 
 
178 
37 
4 
1 
 
88 
19 
3 
2 
WBC: 
0-9.9 
10-49.9 
50-99.9 
100+ 
Median 
Range 
 
138 (63%) 
61 (28%) 
15 (7%) 
6 (3%) 
5.8 
0.4-177.7 
 
65 (58%) 
34 (30%) 
9 (8%) 
4 (4%) 
5.5 
0.5-249.0 
Cytogenetics 
Intermediate 
Unknown 
 
194 (88%) 
26 (12%) 
 
106 (95%) 
6 (5%) 
FLT3 ITD 
WT 
Mutant 
Unknown 
 
199 (96%) 
8 (4%) 
13 
 
101 (99%) 
1 (1%) 
10 
NPM1c 
WT 
Mutant 
Unknown 
 
132 (65%) 
70 (35%) 
18 
 
61 (61%) 
39 (39%) 
12 
FLT3 TKD 
WT  
Mutant 
Unknown 
 
204 (99%) 
3 (1%) 
13 
 
100 (98%) 
2 (2%) 
10 
Induction chemotherapy 
ADE (not randomised) 
 
ADE 
ADE+GO3 
ADE+GO6 
DA+GO3 
DA+GO6 
 
DA 90mg 
DA 60mg 
 
13 (6%) 
 
29 (13%) 
26 (12%) 
26 (12%) 
22 (10%) 
26 (12%) 
 
37 (17%) 
41 (19%) 
 
7 (6%) 
 
14 (13%) 
14 (13%) 
14 (13%) 
11 (10%) 
12 (11%) 
 
19 (17%) 
21 (19%) 
Post Course 1 Risk Score 
Good risk 
Standard Risk 
 
27 (13%) 
193 (87%) 
 
11 (10%) 
101 (90%) 
MRD status post course 1 (CR 
only) 
CR, MRD -ve 
CR, MRD +ve 
No MRD data/no CR 
 
 
43 (20%) 
63 (29%) 
114 (52%) 
 
 
24 (21%) 
24 (21%) 
64 (57%) 
Transplanted 
Any allograft 
Any transplant in CR1 
Allograft in CR1 
85 (39%) 
69 (31%) 
24 (11%) 
20 (9%) 
47 (42%) 
38 (34%) 
16 (14%) 
14 (13%) 
 
  
 
Table 2: Clinical Outcomes by Treatment Arm 
 
 Everolimus Control OR/HR & CI P-
value 
CR/CRi 99% 99% 1.02 (0.09-
11.2) 
1.0 
MRD positivity post course 2 (CR 
only) 
63% 65% 1.07 (0.50-
2.33) 
0.9 
30-day mortality 1% 1% 1.48 (0.19-
11.7) 
0.7 
60-day mortality 4% 1% 2.77 (0.70-
11.0) 
0.15 
5 year OS 45% 58% 1.30 (0.94-
1.81) 
0.11 
5 year RFS 29% 40% 1.19 (0.90-
1.59) 
0.2 
5 year cumulative incidence of 
relapse 
60% 54% 1.12 (0.82-
1.52) 
0.5 
6 month death in CR 8% 1% 3.57 (1.36-
9.42) 
0.009 
5 yr cumulative incidence of death in 
CR 
11% 6% 1.75 (0.83-
3.70) 
0.14 
5 yr survival post relapse 19% 30% 1.17 (0.81-
1.70) 
0.4 
5 yr OS censored at SCT 57% 66% 1.34 (0.87-
2.06) 
0.18 
 
 
 
 
 
  
 
Table 3: Recovery and Supportive Care in Everolimus Randomisation 
 
 
   Randomisation 
 
 
Type of Care Course  Everolim
us 
   Control  p-value 
Neutrophil recovery (median 2  28  29  0.4 
From start of course 3  29  27  0.08 
        
Platelet recovery (median 2  38  29  0.006 
From start of course 3  42  36  0.10 
        
        
Blood (mean units) 2  4.6  5.0  0.08 
 3  6.3  6.1  0.5 
Platelets (mean units) 2  5.1  3.7  0.009 
 3  6.4  5.5  0.4 
Antibiotics (mean days) 2  10.2  7.7  0.002 
 3  12.5  10.8  0.14 
Hospitalisation (mean days) 2  25.2  22.3  0.02 
 3  24.8  23.5  0.3 
        
Hospitalisation (median days) 2  25.5  23   
 3  25  24.5   
        
† Logrank test.   * Wilcoxon test 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure Legends: 
 
Figure 1: CONSORT diagram 
 
Figure 2: Compliance with treatment 
 
Figure 3 Toxicity associated with treatment in courses 2 and 3. A) Course 2; 
B) Course 3 of treatment 
 
Figure 4: Relapse, Death in Remission, Relapse Free Survival and Overall 
Survival within the Everolimus Randomisation: A) Cumulative Incidence of 
Relapse; B) Cumulative Incidence of Death in Remission; C) Relapse Free 
Survival; D) Overall Survival 
 
 
 




 
 
Supplemental Figure 1: Randomisations Addressed in AML17 
 
Protocol Version 7 
 
 
Gemtuzumab Ozogamicin 3mg/m2 vs 6mg/m2 (day 1 course 1) 
ADE vs DA 
DA (Daunorubicin 90mg/m2) vs DA (Daunorubicin 60mg/m2) 
Lestaurtinib vs not (FLT3 mutant) 
Everolimus vs not (courses 2-4) 
3 vs 4 courses in total (if not high risk) 
FLAG-Ida vs Daunorubicin/Clofarabine 
 
  
 
Supplementary Figure 2: Plasma Inhibitory activity (PIA) Measurement. 
 
The protocol requested, with patient agreement, the collection of blood samples pre-dose on day 
14 of each course of everolimus treatment. To assess mTOR inhibitory activity, 400μl patient plasma 
was incubated in triplicate with 5x105 HEL cells for 1h at 37°C in a humidified incubator with 5%CO2. 
The approach was similar to those reported for other inhibitory assays.18 A standard curve of 
phospho-S6 ribosomal protein (pS6-RP) PIA versus everolimus concentration was generated by 
spiking healthy volunteer plasma with everolimus that produce clinically-relevant concentrations 
ranging from 1 to 200ng/ml. In this context an estimate of plasma inhibition of phospho-S6 ribsomal 
protein (p S6-RP) in response to patient plasma was measured in cell lysates by immunoblotting 
and ELISA. The results were expressed as a percentage reduction of pS6-RP inhibitory activity 
compared to the maximum inhibition achieved by a 200ng/ml everolimus concentration which was 
run in parallel along with a no drug control.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 3: Resolution of Sanger data with AML17 mTOR randomisation 
(n=124) 
 
 
 Mutations in the following genes were found in only one patient and are not shown in the graph: 
 
ATRX ERCC2 KIAA1267 PTEN SMG1 
CBFB FBXW7 LUC7L2 PTPRF STAG1 
CBLB GATA1 MED12 SF1 U2AF2 
CBLC KDM6A MYH11 SF3B1 ZRSR2 
CSF3R     
 
  
Supplementary Figure 4: Stratified analysis of Relapse Free Survival. A) Demographics; B) 
Mutation status (minimum 10 mutant patients with RFS data) 
A)
 
  
B)
 
  
 Supplementary Figure 5: Relapse Free Survival Related to Treatment Compliance. 
 
